The concept of the use of antioxidants as a therapeutic intervention to prevent coronary artery disease arose from the oxidized low-density lipoprotein theory of atherosclerosis. Once it was recognized that antioxidants could prevent free-radical species from oxidizing lipoproteins, investigators began to explore the relationship between antioxidants and atherosclerotic cardiovascular disease in large population-based studies. Many of these early studies demonstrated an inverse relationship between antioxidant levels and adverse cardiac events. Although these observations fueled interest in randomized clinical trials, results from many trials were disappointing, with little or no observed benefit of antioxidant supplementation in reducing cardiovascular risk. Although several theories have attempted to explain the discrepancy between laboratory studies and clinical trials, to date it remains an unresolved issue. This review will examine the role of antioxidants in mediating the pathological processes involved in atherosclerosis, discuss the results from key trials on antioxidants and cardiac events, and present a rationale for further studies in this field.
Oxidant stress, antioxidants, and atherosclerosis
In the cardiovascular system, cells constantly generate reactive oxygen species (ROS) that are utilized as signaling molecules. These ROS are an integral component of cellular homeostatic processes and operate within a redox environment that is balanced by intracellular and extracellular antioxidants. The critical role of these antioxidants is realized when ROS levels exceed the cellular antioxidant capacity and create a state of oxidant stress. When oxidant stress is present, ROS may oxidatively modify or damage lipids, proteins, and DNA, with deleterious consequences for vascular function and structure [1, 2] .
The complexity of the cardiovascular antioxidant system is highlighted by the array of enzymatic and nonenzymatic factors that serve as antioxidants to reduce cellular ROS to less reactive forms ( Fig. 1 ; reviewed by Leopold and colleagues [1, 2] ). There are a several key cellular and circulating antioxidant systems, including superoxide dismutases, glutathione peroxidases, and catalases, that collectively reduce superoxide/hydrogen peroxide (or lipid hydroperoxides) to water (or lipid hydroxides). There are also many important smallmolecule antioxidants such as α-tocopherol, ascorbic acid, β-carotene, and reduced glutathione (GSH). The enzyme glutathione reductase maintains intracellular levels of GSH by reducing glutathione disulfide in a reaction that requires NADPH, which is supplied by glucose-6-phosphate dehydrogenase. Thus, when antioxidant activity is decreased or small-molecule antioxidant availability is limited, oxidant stress may occur as a result of diminished net antioxidant capacity [1, 2] .
Oxidant stress promotes atherosclerosis through a number of complementary mechanisms. When present, oxidant stress causes endothelial dysfunction, activates inflammation, immune responses, and thrombus formation, oxidizes lipids, and initiates a cascade of vascular events that is permissive for the formation of atherosclerotic plaques (reviewed by Leopold and colleagues [1, 2] ). The link between oxidant stress and atherosclerosis has been confirmed in a number of studies that have measured elevated markers of oxidant stress in patients and shown that they are predictive of coronary artery disease [3] . For example, the F 2 -isoprostanes, which are considered reliable markers of oxidant stress, are independent predictors of significant coronary artery disease [odds ratio = 9.7; 95% confidence interval (CI): 2.6-36.9, P = 0.016] [4] [5] [6] [7] . Moreover, a case-control study found a 30.8-fold increased risk for coronary artery disease among individuals whose F 2 -isoprostane levels were in the highest tertile [5] . Lipid hydroperoxides are also recognized as markers of increased oxidant stress and are independent predictors for major adverse cardiovascular events (hazard ratio = 2.23, 95% CI for relative risk: 1.44-3.44, P < 0.0003) [8] . Thus, there are multiple lines of evidence that indicate that systemic oxidant stress is associated with atherosclerosis.
Another piece of confirmatory evidence relating oxidant stress to atherosclerosis was obtained from studies that examined plasma levels of antioxidants. The premise behind these studies was that lower levels of antioxidants would also increase oxidant stress. Among the circulating proteins with antioxidant function, such as uric acid, albumin, haptoglobin, transferrin, ceruloplasmin, and GSH, levels of GSH have been inversely related to atherosclerosis [9] . One study of 114 healthy individuals without known atherosclerosis found an inverse correlation between GSH levels and carotid intima-medial thickness [10] . Other studies were designed to determine the protective effects of dietary antioxidants such as β-carotene and related carotenoids, ascorbic acid, and αtocopherol. The carotenoids are fat-soluble free-radical scavengers that are typically found in yellow-orange fruits and vegetables, as well as in leafy green vegetables. Of these, α-carotenes and β-carotenes are provitamin A carotenoids, whereas lutein and lycopene cannot be converted to retinol and do not possess vitamin A activity [9] . Ascorbic acid (vitamin C) is a water-soluble antioxidant in humans that serves as an electron donor and is capable of reducing oxidized species. Ascorbic acid is particularly high in content in citrus and other fruits and is found in vegetables, including leafy greens, tomatoes, and peppers. The fat-soluble antioxidant αtocopherol (vitamin E) exists in eight different forms that reduce ROS by donating a hydrogen atom. In the diet, αtocopherol is found in vegetable oils, as well as in whole grains, nuts and seeds, and green leafy vegetables [9] .
The relationship between the levels of these antioxidants in the bloodstream in the absence of supplementation and atherosclerosis risk was examined in several cohorts of healthy individuals. In one population-based study ), which is dismutated to hydrogen peroxide (H 2 O 2 ), which is also an oxidant that is reduced to water by the glutathione peroxidases (GPx). This involves a series of coupled reactions that requires the small-molecule antioxidant reduced glutathione (GSH), which is generated through the actions of glutathione reductase (GSSG Red) and glucose-6-phosphate dehydrogenase (G6PD). GSH is also required for the antioxidant actions of ascorbic acid and to regenerate α-tocopherol, which reduces oxidized lipids (LOO • ) that are generated by hydroxyl radicals ( • OH − ). These oxidized lipids are reduced (LOOH) through a series of reactions that involves the antioxidant β-carotene. When there is an increase in reactive oxygen species (ROS) generation and/or a decrease in antioxidant capacity, then oxidant stress occurs. This facilitates the development of atherosclerosis by causing oxidation of proteins, lipids, and DNA, as well as by promoting inflammation and vascular dysfunction (reviewed in Leopold et al. [1] ). that included 392 individuals, plasma levels of α-carotene and β-carotene were found to be decreased significantly in tobacco users and independently and inversely associated with prevalent carotid atherosclerosis [11] . Plasma levels of ascorbic acid were also found to be inversely related to coronary calcium levels, a marker of atherosclerosis, in a study of 2637 young (age 18-30 years) individuals who participated in the Coronary Artery Risk Development in Young Adults (CARDIA) study [12] . These studies indicate that in healthy individuals who are not taking supplements, lower levels of selected carotenoids and ascorbic acid compounds are associated with decreased plasma antioxidant capacity and increased risk for atherosclerosis [10] .
Observational studies on antioxidants and cardiovascular risk
Owing to the fact that decreased plasma antioxidant levels were associated with an increased risk for atherosclerosis, large-scale population-based studies were investigated to confirm this association across a broad demographic. These early studies focused mainly on the antioxidants β-carotene, ascorbic acid, and α-tocopherol and how their intake was related to the risk for atherosclerosis and major adverse events. This was done, in part, to understand whether dietary antioxidants could explain the observed differences in cardiovascular risk seen between patient populations and to provide a rationale for introducing these compounds as dietary supplements to decrease cardiovascular risk.
Enthusiasm for trials on antioxidant supplementation came from studies like the Health Professionals Followup Study, which included 39 910 male healthcare professionals followed up for 4 years. This study found that β-carotene decreased cardiovascular events [relative risk (RR) = 0.71; 95% CI: 0.55-0.92, P = 0.02] [13] . When the data were examined further, it turned out that current smokers had the greatest risk reduction (RR = 0.30; 95% CI: 0.11-0.82) as compared with former or never smokers [13] . The Nurses Health Study, which included 73 286 nurses followed up for 12 years, also found an inverse association between dietary carotenoid levels and incident coronary artery disease (RR = 0.74; 95% CI: 0.59-0.93) [14] . More recently, the National Health and Nutritional Examination Study (NHANES III) reported on 13 293 participants followed up for up to 18 years. This study also found that higher α-carotene and β-carotene levels were associated with lower rates of cardiovascular mortality [15] .
Many of the aforementioned studies also examined the relationship between ascorbic acid or α-tocopherol and cardiovascular disease. Epidemiological studies on ascorbic acid yielded mixed results. Findings from the NHANES III and Eastern Finland Study suggested that ascorbic acid was associated with a decreased risk for cardiovascular and coronary artery diseases [16, 17] . The ARIC trial and Rotterdam studies both examined markers of peripheral arterial disease and also found that ascorbic acid intake was protective but only in women [18, 19] . By contrast, the Health Professionals Follow-up Study, Nurses Health Study, and Iowa Women's Health Study all reported that ascorbic acid had no protective benefit in preventing coronary disease in either men or women [20] .
The epidemiological data supporting an association between α-tocopherol intake and cardiovascular risk reduction were much stronger. The Nurses Health Study and the Iowa Women's Study both reported that vitamin E intake, either from food sources or supplements, had a protective effect and lowered the risk for cardiovascular disease by ∼ 34% and cardiac death by ∼ 58% [21, 22] . Findings from this study suggested further that adequate doses of α-tocopherol taken for more than 2 years were required to achieve the antioxidant benefit. Key findings from the Health Professionals Follow-up study indicated that individuals taking 60 IU/day had an ∼ 40% reduction in the risk for cardiovascular disease compared with individuals taking less than 7.5 IU/day [13] . Although these epidemiological studies generated excitement with regard to the protective benefit of antioxidants, when considered together it is clear that they have a number of limitations that may have influenced the outcomes. The metric by which antioxidant intake was assessed, the lack of measures of plasma antioxidant levels, and other potential confounders such as healthy lifestyle behaviors that correlate with antioxidant intake may have played a role in the positive outcomes.
Early large-scale clinical trials on antioxidants and cardiovascular disease prevention
The somewhat encouraging findings from observational studies were used as the basis to support a number of randomized primary and secondary prevention clinical trials. The primary prevention Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study examined cardiovascular disease as a secondary outcome in 29 133 male smokers randomized to α-tocopherol, β-carotene, a combination of the two, or placebo. At 8 years of followup, neither antioxidant was found to decrease cardiovascular disease [23] [24] [25] . Similarly, the Beta-Carotene and Retinol Efficacy Trial (CARET) was terminated early after finding that β-carotene and retinol (vitamin A) had no effect on incident cardiovascular disease [26, 27] . Similarly, negative findings were also reported in the Vitamin E Atherosclerosis Prevention Study (VEAPS). This study randomized 353 participants with elevated low-density lipoprotein cholesterol levels (>130 mg/dl) to α-tocopherol or placebo and examined the intima-media thickness every 3 months for up to 3 years. Despite evidence that plasma α-tocopherol levels were increased, there was no effect of α-tocopherol on the progression of carotid atherosclerosis over the entire study period [28] .
Although the early primary prevention trials reported negative findings, secondary prevention studies suggested that antioxidants reduce cardiovascular risk in patients with established disease. The Cambridge Heart Antioxidant Study (CHAOS) randomized 2002 individuals with angiographically proven coronary artery disease to α-tocopherol (800 IU/day) or placebo. After a median follow-up of 510 days, patients randomized to α-tocopherol were found to have a reduction in the combined primary endpoint of cardiovascular death and nonfatal myocardial infarction (RR = 0.53; 95% CI: 0.34-0.83, P = 0.005), which was driven mainly by a reduction in myocardial infarction [29] . Despite this, other studies did not have such encouraging results. The Heart Outcomes Prevention Evaluation, which randomized 9927 high-risk patients to α-tocopherol, ramipril, a combination of both, or placebo found that α-tocopherol had no effect on cardiovascular outcomes [30] . Similar negative findings were also reported by the MRC/BHF Heart Protection Study and the Women's Angiographic Vitamin and Estrogen (WAVE) trial [9] .
Contemporary clinical trials on antioxidants and cardiovascular disease prevention
Studies conducted in the contemporary era have continued to explore the question of whether or not antioxidants can prevent cardiovascular disease; however, the outcomes have not changed significantly (Fig. 2) . In fact, several primary prevention studies have yielded disappointing results. The Women's Health Study randomized 39 876 individuals in a 2 × 2 factorial design to α-tocopherol or placebo and aspirin or placebo and followed up participants for an average of 10.1 years. In this study, α-tocopherol supplementation decreased cardiovascular mortality in healthy women (RR = 0.76; 95% CI: 0.59-0.98, P = 0.03) but had no effect on the incidence of myocardial infarction or stroke [31] . These results were confirmed by the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) study. This trial enrolled 13 017 French adults who were randomized to a capsule that contained ascorbic acid, selenium, zinc, α-tocopherol, and β-carotene or to placebo. There were no differences detected between the groups with respect to the incidence of ischemic cardiovascular disease after a median of 7.5 years despite the fact that the supplement did increase blood levels of the vitamins and minerals [32] .
These disappointing findings were also seen in largescale studies on secondary prevention. For example, the Women's Antioxidant Cardiovascular Study examined daily ascorbic acid with every other day α-tocopherol and β-carotene as the antioxidant cocktail. In this study, 8171 female healthcare professionals with a history of cardiovascular disease or three or more risk factors were followed up for a mean of 9.4 years. Antioxidant treatment had no effect on the combined endpoint of cardiovascular death, myocardial infarction, stroke, or revascularization.
In a prespecified analysis, the study did report an 11% decrease in the combined endpoint in women who had established cardiovascular disease compared with those without disease [33] . In another substudy, 5442 women were enrolled in a placebo-controlled trial to receive a combination pill that contained folic acid, vitamin B6, and vitamin B12, or placebo. After a mean follow-up of 7.3 years, there was no difference observed between the active treatment and placebo groups with respect to any cardiovascular outcome [34] . These negative findings were confirmed in a randomized trial involving Norwegian patients and in the Western Norway B Vitamin Intervention Trial [35, 36] . Another study attempted to determine whether the failure of B vitamins occurred as a result of missing cofactors. In this study, 2501 French patients with a history of symptomatic cardiovascular disease were randomized to a supplement that contained 5-methytretrahydrofolate, vitamin B6, and vitamin B12 versus placebo and a supplement that contained omega-3 fatty acids or placebo in a 2 × 2 factorial design. Omega-3 fatty acids had been added as another putative antioxidant owing to their ability to prevent lipid oxidation. Although homocysteine levels were decreased by 19% with the combination supplement compared with placebo, neither treatment had an effect on cardiovascular events [37] . These outcomes were also observed in the Supplementation with Folate, vitamin B6 and B12 and/or Omega-3 fatty acids (SU.FOL.OM3) trial [38] . Perhaps the most significant negative report came from The Physician's Health Study II that enrolled 14 641 male physicians, including 754 participants with a history of cardiovascular disease. This study randomized participants to a multivitamin daily or to placebo and the individuals were followed up for a median of 11.2 years. At the end of the study, multivitamin treatment was not found to decrease major cardiovascular events and had no effect on myocardial infarction, stroke, or cardiovascular mortality. These findings remained consistent whether the multivitamins were given as primary or secondary prevention [39] .
To reconcile all the available data from clinical studies, several meta-analyses were carried out. One analysis included data from 188 209 individuals who participated in 15 placebo-controlled clinical trials. Overall, this study found that antioxidant vitamins had no effect on major adverse cardiovascular events (RR = 1.00, 95% CI: 0.96-1.03). This meta-analysis, however, was limited by the use of pooled and not patient-level data and could not account for potential differences as a result of supplement dose and follow-up times [40] . Another metaanalysis identified 50 randomized controlled trials that included 294 478 participants (156 663 in the treatment or intervention group and 137 815 in the control or referent group) to evaluate the effect of antioxidants on cardiovascular disease. Using a fixed effects model, the primary analysis found that vitamins or antioxidant supplements did not reduce the risk for major cardiovascular events (RR = 1.00; 95% CI: 0.98-1.02), leading to the conclusion that antioxidant vitamins or supplements had no beneficial effect in the primary or secondary prevention of cardiovascular disease [41] .
Why have trials on antioxidants failed?
Despite the abundance of laboratory and observational study evidence indicating that antioxidants should prevent cardiovascular disease, the results from large-scale randomized clinical trials have been disappointing. A number of theories to explain the discrepancy between observational studies and clinical trials have been put forward (Table 1) . First, it has been suggested that the wrong antioxidants were trialed and that the cardiovascular risk reduction seen in dietary studies was related to other compounds in the foods consumed [42] . A related theory is that synthetic versions of the antioxidants administered in clinical intervention trials may not completely mimic the natural forms of the antioxidants. Second, not all antioxidants are functionally similar, and those included in clinical trials may have different threshold effects for abrogating cellular processes related to oxidant stress and the pathogenesis of atherosclerosis. Many of the studies did not include a metric to determine whether the dose of the antioxidant given in the trial actually decreased oxidant stress and did not examine dose-response [43] . This means that it is possible that individuals were either undertreated or not treated for a long enough duration to demonstrate any effect. This is important to consider as different doses of α-tocopherol have been shown to have a dose-response effect with respect to markers of oxidant stress, with an ∼ 35% decrease in the oxidant stress marker F 2 -isoprostane after 1600 IU and an ∼ 49% decrease after 3200 IU [43] . There is also the issue of interindividual variability in metabolism, as well as safety. As many studies were conducted in the era before standardized safety testing, it is unknown whether these antioxidants are safe at the doses required to lower oxidant stress [44, 45] . Finally, because patients were not screened for trials on the basis of their antioxidant capacity, it is possible that some patients who would derive no benefit from supplemental antioxidants were included in the studies. This is particularly important in an era in which patients are being treated with statins, as studies on statins plus antioxidant vitamins have found that there was no additional benefit from the vitamin supplements [46, 47] .
Other antioxidants being investigated in cardiovascular disease prevention
The suggestion that the wrong antioxidants were being studied led investigators to consider selenium as a 
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Myung et al. [41] Physicians Health Study II [39] SU.FOL.OM3 [37] WAFACS [34] Ebbing et al. [35] Women's Antioxidant Study [33] SU.VI.MAX [32] Women's Health Study [31] Intervention better [31] [32] [33] [34] [35] 37, 39, 41] . possible newer antioxidant worthy of investigation. Selenium is a nonmetal trace element that is required for the formation of selenoproteins, such as the antioxidant enzymes glutathione peroxidase and thioredoxin reductase. Dietary sources of selenium include nuts, particularly Brazil nuts, cereals, meats, tuna, eggs, and mushrooms. Clinical trials on selenium supplementation for the primary prevention of cardiovascular disease have been conducted. Twelve randomized controlled trials involving 19 715 patients who were followed up for 3 months or longer were included in a meta-analysis. This analysis found that selenium supplementation had no effect on all-cause or cardiovascular mortality and no effect on any major adverse cardiovascular event. In addition, in some trials selenium supplementation was found to be associated with alopecia and dermatitis as adverse effects. On the basis of the limited trial data available, it was felt that there was not enough evidence to support the use of selenium for primary prevention of cardiovascular disease [48] .
Another factor considered for its antioxidant properties is the coenzyme Q10. Coenzyme Q10 is a lipid-soluble mitochondrial electron carrier that is involved in ATP production. Coenzyme Q10 has antioxidant functions and prevents lipid oxidation. As synthesis of coenzyme Q10 shares the same pathway as cholesterol, statins are believed to decrease coenzyme Q10 levels by up to 40%. There is very limited information to determine whether coenzyme Q10 would prevent cardiovascular disease; however, a meta-analysis that included 12 trials with 362 patients found that coenzyme Q10 supplements decreased blood pressure with a drop in systolic blood pressure of 11-17 mmHg and diastolic blood pressure of 8-10 mmHg compared with placebo; however, owing to the unreliability of some of the included studies, no recommendations could be made [49] . Another metaanalysis that included 194 patients found that coenzyme Q10 improves endothelial function, as assessed by flowmediated dilatation (SMD 1.70, 95% CI: 1.00-2.4, P < 0.0001) [50] . Although these early studies are encouraging, this antioxidant remains to be studied in adequately powered large-scale randomized trials.
Fruit and vegetable dietary intervention
Given the findings from clinical trials on synthetic antioxidant supplements, there has been a renewed interest in studying dietary antioxidants that are consumed through fruit, vegetable, and nut intake. This has led to dietary intervention studies that have attempted to assess the effect of increasing consumption of antioxidant foods on cardiovascular disease risk. The beneficial antioxidant effects of diet have been examined extensively in the PREvención con DIeta MEDiterránea (PREDIMED) study, a multicenter, randomized, controlled, clinical trial that evaluated the effects of a Mediterranean diet on cardiovascular outcomes in individuals without cardiovascular disease. Participants were randomized to a Mediterranean diet supplemented with nuts or extra-virgin olive oil, or a control low-fat diet. After a median of 4.8 years, there was a 28-30% reduction in major adverse cardiovascular events in individuals randomized to the supplemented Mediterranean diet (Fig. 3) [51] . These findings were attributed, in part, to a reduction in oxidant stress, as markers of oxidant stress (i.e. oxidized low-density lipoproteins and malondialdehyde) were decreased in individuals assigned to the Mediterranean diet [52] . Although it is not clear what dietary antioxidants are responsible for the cardiovascular risk reduction, it is evident that dietary intervention with the Mediterranean diet offered the best possible outcomes of all the antioxidants studied.
Conclusion
There is clear and convincing evidence that oxidant stress is involved in the pathogenesis of atherosclerosis, and this alone provides a compelling argument that antioxidants should decrease the risk for atherothrombotic cardiovascular diseases. Yet, after 20 + years of clinical trials that studied the effect of supplemental antioxidants on incident cardiovascular disease, there are no overarching data to indicate that this intervention works. Laboratory investigations are continuing to advance our understanding of oxidant stress and the related issue of reductive stress (i.e. too much antioxidant), and are aiding in the identification of new antioxidants. On the basis of this, it is plausible that there may be some role of antioxidant therapies in the prevention of cardiovascular Mediterranean diet and cardiovascular outcomes. Individuals enrolled in the PREvención con DIeta MEDiterránea (PREDIMED) study were randomized to a Mediterranean diet supplemented with extra-virgin olive oil or nuts versus a low-fat diet and followed up for a median of 4.8 years. The primary endpoint was a composite of myocardial infarction, stroke, and cardiovascular death. The primary endpoint was adjusted for sex, age, family history of premature coronary disease, tobacco use, BMI, waist-to-height ratio, and the presence of hypertension, hyperlipidemia, and diabetes at baseline. CI, confidence interval; CV, cardiovascular; MI, myocardial infarction. Data from Estruch et al. [51] . disease, and new trials on antioxidants could start again. In order for these trials to have a chance at success, trial design will be critical. In future studies, patient selection on the basis of distinct measures of oxidant stress and antioxidant capacity, formal dose-response and safety testing, and realistic timing of the intervention would have to be considered. Other issues to be considered include the antioxidant selected for trial and possible vascular-specific delivery using targeted small molecules or nanoparticles. Owing to the recent positive findings with the Mediterranean diet, studies should also consider dietary modification as a part of the intervention. Given the intense interest in this avenue of investigation, it is likely that there will be many more trials that examine the role of antioxidants in preventing cardiovascular disease.
